Medscape

DVT Prevention: Aspirin, Rivaroxaban Similar After Arthroplasty

Among patients who underwent total hip or total knee arthroplasty, aspirin did not differ significantly from rivaroxaban (Xarelto, Janssen Pharmaceutica) for prevention of proximal deep-vein ...
Healio

Rivaroxaban may reduce post-osteotomy thromboembolic events better than aspirin

CHICAGO — Use of rivaroxaban may reduce the risk of thromboembolic events after osteotomy, according to results presented at the Arthroscopy Association of North American Annual Meeting. Perspective ...
FierceBiotech

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...
Medscape

PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis

Rivaroxaban (Xarelto, Bayer/Janssen) was superior to enoxaparin in preventing venous thromboembolism (VTE) in patients immobilized by nonmajor orthopedic surgical procedures, in a new randomized trial ...
TCTMD

FDA Gives Rivaroxaban Another VTE-Related Indication

Rivaroxaban (Xarelto; Bayer/Janssen) has gained an additional indication, this time for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients at increased risk for ...
National Institute for Health and Care Excellence

Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...
FiercePharma

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...
TCTMD

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

(UPDATED) A standard dose of rivaroxaban (Xarelto; Bayer/Janssen) reduces the combined risk of venous and arterial thromboembolic events after discharge among patients recently hospitalized for acute ...
Monthly Prescribing Reference

Xarelto sNDA Submitted for VTE Prophylaxis in Acute Medically Ill

The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and ...
Monthly Prescribing Reference

Xarelto Safety, Efficacy for DVT Confirmed in Real-World Data

Janssen and Bayer announced the results from their real-world study XALIA, showing that the rates of major bleeding and recurrent blood clots for Xarelto (rivaroxaban) in routine clinical practice ...
The American Journal of Managed Care

Venous Thromboembolism in Acute Medically Ill Patients: Identifying Unmet Needs and Weighing the Value of Prophylaxis

Stakeholders concurred that the occurrence of VTE events is a significant public health concern. According to Ralph J. Riello III, PharmD, “It is a problem often that hospitals do not know that they ...
FierceBiotech

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...